DaVita Inc. Q1 2026 10-Q Summary
Business Context and Reporting Period
This report covers the quarterly period ended March 31, 2026. DaVita Inc. is a leading provider of kidney dialysis services in the United States, operating through its U.S. dialysis segment and ancillary services (including Integrated Kidney Care, international operations, and other services). The company reported a large accelerated filer status with approximately 64.2 million shares of common stock outstanding as of May 5, 2026.
Key Financial Metrics
| Metric | Q1 2026 | Q1 2025 |
|---|---|---|
| Total Revenues | $3,415.5 million | $3,223.5 million |
| Operating Income | $481.9 million | $438.9 million |
| Net Income (Consolidated) | $275.0 million | $232.2 million |
| Net Income Attributable to DaVita | $197.5 million | $162.9 million |
| Diluted EPS (DaVita) | $2.87 | $2.00 |
| Operating Cash Flow | $320.8 million | $180.0 million |
| Free Cash Flow | $140.0 million | ($45.0 million) |
| Total Debt (Principal) | $10,694.3 million | $10,344.6 million |
| Cash and Equivalents | $644.2 million | $676.4 million |
| Available Liquidity (Revolving Credit) | $1,125.0 million | N/A |
Material Changes vs. Prior Period
- Revenue Growth: Consolidated revenues increased 6.0% year-over-year (YoY) to $3.416 billion, driven by a 4.2% increase in U.S. dialysis revenues and a 20.0% increase in ancillary services revenues.
- Profitability: Operating income rose 9.8% YoY to $481.9 million. U.S. dialysis operating income increased 6.3% to $506 million, while ancillary services turned a loss into a profit of $6 million (compared to a $3 million loss in Q1 2025).
- Cost Trends: U.S. dialysis patient care costs per treatment increased 3.1% YoY to $280.11, primarily due to higher compensation and insurance costs. General and administrative expenses increased 13.1% YoY due to IT and compensation costs.
- Cash Flow: Operating cash flow surged 78.3% YoY to $320.8 million, aided by improved working capital management. Free cash flow improved significantly to $140 million from a negative $45 million in the prior year.
- Debt: Total debt principal increased by approximately $350 million, reflecting new borrowings and the issuance of 6.75% Senior Notes in 2025. The weighted average effective interest rate decreased to 5.44% from 5.65%.
Outlook, Risks, and Unusual Items
- Guidance and Outlook: Management expects treatment volumes to remain flat to slightly positive, driven by lower mortality rates offset by lower new admissions. They anticipate continued productivity improvements to offset inflationary labor and supply costs. No specific full-year financial guidance numbers were provided in this text.
- Strategic Initiatives: On February 2, 2026, DaVita signed an agreement to acquire a noncontrolling minority interest in Elara Caring for approximately $200 million, expected to close mid-2026.
- Share Repurchases: The company repurchased 3.0 million shares for $402.9 million in Q1 2026. As of May 5, 2026, approximately $1.456 billion remained available under current authorizations.
- Risks and Contingencies:
- Legal Proceedings: The company faces ongoing investigations, including a 2020 U.S. Attorney investigation (New Jersey/Pennsylvania) regarding joint ventures and compliance, a 2020 California Department of Insurance investigation, and a 2024 FTC investigation into antitrust matters regarding medical director services. A 2021 antitrust class action regarding non-solicitation agreements is ongoing.
- Regulatory Environment: Risks include potential changes to Medicare/Medicaid reimbursement rates, the impact of the "One Big Beautiful Bill Act" (OBBBA), and trade policies affecting supply chains.
- Cybersecurity: The company references the impact of a 2025 cybersecurity incident on billing and collections, though no specific financial impact was quantified in this summary.
Investor Verification Checklist
- Revenue Mix: Verify the sustainability of the 4.4% increase in average patient service revenue per treatment and the shift in payor mix (Medicare vs. Commercial).
- Cost Inflation: Monitor the trajectory of patient care costs per treatment, specifically wage rates and pharmaceutical costs, to ensure they do not outpace revenue growth.
- Legal Exposure: Assess the potential financial impact of the ongoing FTC antitrust investigation and the New Jersey/Pennsylvania False Claims Act litigation.
- Debt Servicing: Confirm the company's ability to service its $10.7 billion debt load given the 5.44% effective interest rate and upcoming maturities (e.g., 4.625% Senior Notes in 2030).
- Elara Caring Acquisition: Track the regulatory approval process and integration timeline for the $200 million Elara Caring investment.